Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

BACKGROUND: Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB09004 evaluated masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate dementia due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubois, Bruno, López-Arrieta, Jesús, Lipschitz, Stanley, Triantafyllos, Doskas, Spiru, Luiza, Moroz, Svitlana, Venger, Olena, Vermersch, Patrick, Moussy, Alain, Mansfield, Colin D., Hermine, Olivier, Tsolaki, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972756/
https://www.ncbi.nlm.nih.gov/pubmed/36849969
http://dx.doi.org/10.1186/s13195-023-01169-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972756/
https://www.ncbi.nlm.nih.gov/pubmed/36849969
http://dx.doi.org/10.1186/s13195-023-01169-x

Ejemplares similares